PTC Therapeutics, Inc. logo PTCT - PTC Therapeutics, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 17
HOLD 7
SELL 2
STRONG
SELL 0
| PRICE TARGET: $96.33 DETAILS
HIGH: $120.00
LOW: $85.00
MEDIAN: $90.00
CONSENSUS: $96.33
UPSIDE: 13.53%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Platform & Compounding FCF 85% confidence

Primary model: Two-stage FCF DCF

Valuation Signal Fair Value Moderate
Trading 24.6% below fair value
Current Price $84.85
Bear Case $112.47 32.6% upside ($112.47 - $84.85) / $84.85 = 32.6% 3% stage 1 growth, 11% discount
Fair Value $112.47 32.6% upside ($112.47 - $84.85) / $84.85 = 32.6% 3% stage 1 growth, 11% discount
Bull Case $118.94 40.2% upside ($118.94 - $84.85) / $84.85 = 40.2% 4% stage 1 growth, 11% discount

Adjust Assumptions

3.0%
11.0%
3.0%

Key Value Driver

FCF growth rate (3% base case)

Terminal Value % of EV 33%
Implied Market Multiple 8.6x
Market is pricing in (growth) -2.6% vs our 3.0% base

Plain-Language Summary

Our base-case estimate uses a two-stage discounted cash flow model based on free cash flow. We then blend that result with the average analyst price target of $96.33 from 26 analysts, using a 25% weight on analyst consensus. That produces an estimated intrinsic value of $112.47 per share.

Key Risks

  • P/E alone misleads — earnings depressed by growth investment
  • Cyclical or commodity businesses may be misclassified as platforms
  • Terminal value dominance suggests sensitivity to long-run assumptions